Neurovascular signalling defects in neurodegeneration

Nature Reviews Neuroscience

Volumn 9, Issue 3, 2008, Pages 169-181

  Zacchigna, Serena ^a,b   Lambrechts, Diether ^a,b   Carmeliet, Peter ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIONEURIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS; DEGENERATIVE DISEASE; DEMYELINATION; HUMAN; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER GROWTH; NERVE REGENERATION; NERVOUS SYSTEM; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BLOOD VESSELS; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NERVE DEGENERATION; NEURONS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 39449111508     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn2336     Document Type: Review

References (168)

1. Olofsson, B. & Page, D. T. Condensation of the central nervous system in embryonic Drosophila is inhibited by blocking hemocyte migration or neural activity. Dev. Biol. 279, 233-243 (2005).
2. Popovici, C., Isnardon, D., Birnbaum, D. & Roubin, R. Caenorhabditis elegans receptors related to mammalian vascular endothelial growth factor receptors are expressed in neural cells. Neurosci. Lett. 329, 116-120 (2002).
3. Chao, M. V. Trophic factors: an evolutionary cul-de-sac or door into higher neuronal function? J. Neurosci. Res. 59, 353-355 (2000).
4. Alzheimer, A. Uber eine eigenartig erkrankung der hirnrinde. Psychiatrie Psych. Ger. Med. 65, 146-148 (1907).
5. de la Torre, J. C. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol. Res. 26, 517-524 (2004).
6. Joutel, A. et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383, 707-710 (1996).
7. Kirk, S., Frank, J. A. & Karlik, S. Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? J. Neurol. Sci. 217, 125-130 (2004).
8. Faucheux, B. A., Bonnet, A. M., Agid, Y. & Hirsch, E. C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353, 981-982 (1999).
9. Westin, J. E. et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J. Neurosci. 26, 9448-9461 (2006).
10. Kortekaas, R. et al. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann. Neurol. 57, 176-179 (2005).
11. Marchal, G. et al. PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet 341, 925-927 (1993).
12. Rigau, V. et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 130, 1942-1956 (2007).
13. Sherwood, A., Hinderliter, A. L., Watkins, L. L., Waugh, R. A. & Blumenthal, J. A. Impaired endothelial function in coronary heart disease patients with depressive symptomatology. J. Am. Coll. Cardiol. 46, 656-659 (2005).
14. Veves, A. et al. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47, 457-463 (1998).
15. Kirchmair, R. et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol. Ther. 15, 69-75 (2007).
16. Huang, E. J. & Reichardt, L. F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677-736 (2001).
17. Kermani, P. & Hempstead, B. Brain-derived neurotrophic factor: a newly described mediator of angiogenesis. Trends Cardiovasc. Med. 17, 140-143 (2007).
18. + endothelial cells and systemic mobilization of hematopoietic progenitors. J. Clin. Invest. 115, 653-663 (2005).
19. Capsoni, S. et al. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl Acad. Sci. USA 97, 6826-6831 (2000).
20. Canals, J. M. et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24, 7727-7739 (2004).
21. von Bohlen und Halbach, O., Minichiello, L. & Unsicker, K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of α-synuclein in the substantia nigra. FASEB J. 19, 1740-1742 (2005). This study showed that impairment in TrkB and/or TrkC signalling induces a phenotype in the aged substantia nigra that includes two hallmarks of Parkinson's disease: the loss of tyrosine-hydroxylase-positive neurons and axons and the accumulation of large neuronal deposits of α-synuclein.
22. Lyons, W. E. et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc. Natl Acad. Sci. USA 96, 15239-15244 (1999).
23. Carmeliet, P. Blood vessels and nerves: common signals, pathways and diseases. Nature Rev. Genet. 4, 710-720 (2003).
24. Abid, A., Ismail, M., Mehdi, S. Q. & Khaliq, S. Identification of novel mutations in the SEMA4A gene associated with retinal degenerative diseases. J. Med. Genet. 43, 378-381 (2006).
25. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389-395 (2000).
26. Oosthuyse, B. et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genet. 28, 131-138 (2001). VEGF has always been regarded as the most important and most specific angiogenic factor. This study was the first to show that VEGF also has essential activities in the nervous system.
27. Lambrechts, D. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genet. 34, 383-394 (2003).
28. Shiote, M. et al. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Neuroscience 132, 175-182 (2005).
29. Storkebaum, E. et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neurosci. 8, 85-92 (2005).
30. Wang, Y. et al. VEGF-overexpressing transgenic mice show enhanced post-ischemic neurogenesis and neuromigration. J. Neurosci. Res. 85, 740-747 (2007).
31. Lemmens, R. et al. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum. Mol. Genet. 16, 2359-2365 (2007).
32. Sopher, B. L. et al. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41, 687-699 (2004).
33. Chiappelli, M. et al. VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuvenation Res. 9, 485-493 (2006).
34. Yang, S. P. et al. Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer's disease. Neurobiol. Aging 25, 283-290 (2004).
35. Lopez-Lopez, C., Dietrich, M. O., Metzger, F., Loetscher, H. & Torres-Aleman, I. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. J. Neurosci. 27, 824-831 (2007).
36. Milosevic, J. et al. Lack of hypoxia-inducible factor-1α impairs midbrain neural precursor cells involving vascular endothelial growth factor signaling. J. Neurosci. 27, 412-421 (2007).
37. Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53-67 (2007).
38. Ishii, Y. et al. Mouse brains deficient in neuronal PDGF receptor-β develop normally but are vulnerable to injury. J. Neurochem. 98, 588-600 (2006).
39. Greenway, M. J. et al. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genet. 38, 411-413 (2006). ANG was originally identified as a molecule involved in angiogenic processes. This paper revealed that loss-of-function mutations in the gene cause ALS.
40. Lambrechts, D., Lafuste, P., Carmeliet, P. & Conway, E. M. Another angiogenic gene linked to amyotrophic lateral sclerosis. Trends Mol. Med. 12, 345-347 (2006).
41. Subramanian, V. & Feng, Y. A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum. Mol. Genet. 16, 1445-1453 (2007).
42. Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920-924 (2006). This paper reported that loss-of-funtion mutations in the gene that encodes PGRN cause ubiquitin-positive FTD.
43. He, Z., Ong, C. H., Halper, J. & Bateman, A. Progranulin is a mediator of the wound response. Nature Med. 9, 225-229 (2003).
44. Tangkeangsirisin, W. & Serrero, G. PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 25, 1587-1592 (2004).
45. Tesseur, I. et al. Deficiency in neuronal TGF-β signaling promotes neurodegeneration and Alzheimer's pathology. J. Clin. Invest. 116, 3060-3069 (2006). This article revealed that TGFβRII expression is reduced in early Alzheimer's disease patients, and that neuronal expression of a dominant-negative TGFβRII in the mouse model of AD results in adult-onset neuron loss and symptom aggravation.
46. Brionne, T. C., Tesseur, I., Masliah, E. & Wyss-Coray, T. Loss of TGF-β1 leads to increased neuronal cell death and microgliosis in mouse brain. Neuron 40, 1133-1145 (2003).
47. Buckwalter, M. et al. Molecular and functional dissection of TGF-β1-induced cerebrovascular abnormalities in transgenic mice. Ann. NY Acad. Sci. 977, 87-95 (2002).
48. Gaertner, R. F. et al. Reduced brain tissue perfusion in TGF-β1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities. Neurobiol. Dis. 19, 38-46 (2005).
49. Wyss-Coray, T. et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nature Med. 7, 612-618 (2001).
50. Tooyama, I. et al. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 43, 372-376 (1993).
51. Whitaker, V. R., Cui, L., Miller, S., Yu, S. P. & Wei, L. Whisker stimulation enhances angiogenesis in the barrel cortex following focal ischemia in mice. J. Cereb Blood Flow Metab. 27, 57-68 (2007).
52. Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703 (2007).
53. Ahmad, S. et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ. Res. 99, 715-722 (2006).
54. Zlokovic, B. V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202-208 (2005).
55. Dohgu, S. et al. Transforming growth factor-β1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell. Mol. Neurobiol. 24, 491-497 (2004).
56. Date, I. et al. Hepatocyte growth factor attenuates cerebral ischemia-induced increase in permeability of the blood-brain barrier and decreases in expression of tight junctional proteins in cerebral vessels. Neurosci. Lett. 407, 141-145 (2006).
57. Bendfeldt, K., Radojevic, V., Kapfhammer, J. & Nitsch, C. Basic fibroblast growth factor modulates density of blood vessels and preserves tight junctions in organotypic cortical cultures of mice: a new in vitro model of the blood-brain barrier. J. Neurosci. 27, 3260-3267 (2007).
58. Reuss, B., Dono, R. & Unsicker, K. Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants. J. Neurosci. 23, 6404-6412 (2003).
59. Nico, B. et al. HIF activation and VEGF overexpression are coupled with ZO-1 up-phosphorylation in the brain of dystrophic MDX mouse. Brain Pathol. 17, 399-406 (2007).
60. Croll, S. D., Goodman, J. H. & Scharfman, H. E. Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword. Adv. Exp. Med. Biol. 548, 57-68 (2004).
61. Rite, I., Machado, A., Cano, J. & Venero, J. L. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J. Neurochem. 101, 1567-1582 (2007).
62. Heinicke, K. et al. Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, R947-R956 (2006).
63. Lambrechts, D. & Carmeliet, P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim. Biophys. Acta 1762, 1109-1121 (2006).
64. Zhao, M. et al. Fibroblast growth factor receptor-1 is required for long-term potentiation, memory consolidation, and neurogenesis. Biol. Psychiatry 62, 381-390 (2007). This article showed that FGFR1 is required for the proliferation of neural progenitor cells as well as the generation of new neurons in the adult dentate gyrus. Moreover, deficits in neurogenesis in Fgfr1-mutant mice were accompanied by a severe impairment of LTP and significant deficits in memory consolidation.
65. Holmes, D. I. & Zachary, I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol. 6, 209 (2005).
66. 2+ responses to AMPA and NMDA in hippocampal neurons. J. Neurochem. 65, 2525-2536 (1995).
67. McCloskey, D. P., Croll, S. D. & Scharfman, H. E. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J. Neurosci. 25, 8889-8897 (2005).
68. Qiu, M. H., Zhang, R. & Sun, F. Y. Enhancement of ischemia-induced tyrosine phosphorylation of Kv1.2 by vascular endothelial growth factor via activation of phosphatidylinositol 3-kinase. J. Neurochem. 87, 1509-1517 (2003).
69. Schober, A. et al. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action. Neurobiol. Dis. 25, 378-391 (2007).
70. Sibilia, M., Steinbach, J. P., Stingl, L., Aguzzi, A. & Wagner, E. F. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 17, 719-731 (1998). EGFR has recently been shown to be involved in neurodegeneration: this paper showed that mice that lack EGFR die at 1 month of age due to progressive neurodegeneration that is characterized by the apoptotis of neurons and glia.
71. Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389-1392 (2006).
72. Lu, L. et al. Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J. Neurosci. 27, 7929-7938 (2007).
73. Lievens, J. C., Rival, T., Iche, M., Chneiweiss, H. & Birman, S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum. Mol. Genet. 14, 713-724 (2005).
74. Grothe, C., Haastert, K. & Jungnickel, J. Physiological function and putative therapeutic impact of the FGF-2 system in peripheral nerve regeneration - lessons from in vivo studies in mice and rats. Brain Res. Rev. 51, 293-299 (2006).
75. Ohab, J. J., Fleming, S., Blesch, A. & Carmichael, S. T. A neurovascular niche for neurogenesis after stroke. J. Neurosci. 26, 13007-13016 (2006).
76. Warner-Schmidt, J. L. & Duman, R. S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc. Natl Acad. Sci. USA 104, 4647-4652 (2007).
77. Cao, L. et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nature Genet. 36, 827-835 (2004).
78. Fabel, K. et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur. J. Neurosci. 18, 2803-2812 (2003).
79. Sun, Y. et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 111, 1843-1851 (2003).
80. Louissaint, A. Jr, Rao, S., Leventhal, C. & Goldman, S. A. Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34, 945-960 (2002).
81. Heine, V. M., Zareno, J., Maslam, S., Joels, M. & Lucassen, P. J. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur. J. Neurosci. 21, 1304-1314 (2005).
82. Corti, S. et al. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model. Brain 130, 1289-1305 (2007).
83. Buckwalter, M. S. et al. Chronically increased transforming growth factor-β1 strongly inhibits hippocampal neurogenesis in aged mice. Am. J. Pathol. 169, 154-164 (2006).
84. Holmberg, J. et al. Ephrin-A2 reverse signaling negatively regulates neural progenitor proliferation and neurogenesis. Genes Dev. 19, 462-471 (2005).
85. Ricard, J., Salinas, J., Garcia, L. & Liebl, D. J. EphrinB3 regulates cell proliferation and survival in adult neurogenesis. Mol. Cell. Neurosci. 31, 713-722 (2006).
86. Jacobsen, J. S. et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5161-5166 (2006).
87. Xu, J. Y. et al. Vascular endothelial growth factor inhibits outward delayed-rectifier potassium currents in acutely isolated hippocampal neurons. Neuroscience 118, 59-67 (2003).
88. + channels via phospholipase C and protein kinase C-δ in reactive astrocytes from adult rat brain. J. Biol. Chem. 277, 1974-1980 (2002).
89. Chin, J., Liu, R. Y., Cleary, L. J., Eskin, A. & Byrne, J. H. TGF-β1-induced long-term changes in neuronal excitability in Aplysia sensory neurons depend on MAPK. J. Neurophysiol. 95, 3286-3290 (2006).
90. Akimoto, M. et al. Hepatocyte growth factor as an enhancer of nmda currents and synaptic plasticity in the hippocampus. Neuroscience 128, 155-162 (2004).
91. Maher, F. O., Clarke, R. M., Kelly, A., Nally, R. E. & Lynch, M. A. Interaction between interferon γ and insulin-like growth factor-1 in hippocampus impacts on the ability of rats to sustain long-term potentiation. J. Neurochem. 96, 1560-1571 (2006).
92. Ishiyama, J., Saito, H. & Abe, K. Epidermal growth factor and basic fibroblast growth factor promote the generation of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci. Res. 12, 403-411 (1991).
93. Li, A. J., Suzuki, S., Suzuki, M., Mizukoshi, E. & Imamura, T. Fibroblast growth factor-2 increases functional excitatory synapses on hippocampal neurons. Eur. J. Neurosci. 16, 1313-1324 (2002).
94. O'Kusky, J. R., Ye, P. & D'Ercole, A. J. Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J. Neurosci. 20, 8435-8442 (2000).
95. Lu, B., Pang, P. T. & Woo, N. H. The yin and yang of neurotrophin action. Nature Rev. Neurosci. 6, 603-614 (2005).
96. Pun, S., Santos, A. F., Saxena, S., Xu, L. & Caroni, P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nature Neurosci. 9, 408-419 (2006).
97. Kang, H., Tian, L. & Thompson, W. Terminal Schwann cells guide the reinnervation of muscle after nerve injury. J. Neurocytol. 32, 975-985 (2003).
98. De Winter, F. et al. The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Mol. Cell. Neurosci. 32, 102-117 (2006).
99. Messi, M. L. & Delbono, O. Target-derived trophic effect on skeletal muscle innervation in senescent mice. J. Neurosci. 23, 1351-1359 (2003).
100. Dobrowolny, G. et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 168, 193-199 (2005).
101. Ozdinler, P. H. & Macklis, J. D. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nature Neurosci. 9, 1371-1381 (2006).
102. Szebenyi, G. et al. Fibroblast growth factor-2 promotes axon branching of cortical neurons by influencing morphology and behavior of the primary growth cone. J. Neurosci. 21, 3932-3941 (2001).
103. Caroni, P. & Grandes, P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J. Cell Biol. 110, 1307-1317 (1990).
104. Braak, H. & Del Tredici, K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol. Aging 25, 19-23 (2004).
105. Schratzberger, P. et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nature Med. 6, 405-413 (2000).
106. Kumar, S., Biancotti, J. C., Yamaguchi, M. & de Vellis, J. Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. Neurochem. Res. 32, 783-797 (2007).
107. Li, X., Gonias, S. L. & Campana, W. M. Schwann cells express erythropoietin receptor and represent a major target for Epo in peripheral nerve injury. Glia 51, 254-265 (2005).
108. Zeger, M. et al. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 55, 400-411 (2007).
109. Murtie, J. C., Zhou, Y. X., Le, T. Q., Vana, A. C. & Armstrong, R. C. PDGF and FGF2 pathways regulate distinct oligodendrocyte lineage responses in experimental demyelination with spontaneous remyelination. Neurobiol. Dis. 19, 171-182 (2005).
110. Mason, J. L., Xuan, S., Dragatsis, I., Efstratiadis, A. & Goldman, J. E. Insulin-like growth factor (IGF) signaling through type 1 IGF receptor plays an important role in remyelination. J. Neurosci. 23, 7710-7718 (2003).
111. Le Bras, B. et al. VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. Nature Neurosci. 9, 340-348 (2006).
112. Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. & Gage, F. H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842 (2003).
113. Azzouz, M. et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413-417 (2004).
114. Li, W. et al. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp. Neurol. 203, 457-471 (2007).
115. Musaro, A., McCullagh, K. J., Naya, F. J., Olson, E. N. & Rosenthal, N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400, 581-585 (1999).
116. Arsic, N. et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol. Ther. 10, 844-854 (2004).
117. Shults, C. W., Ray, J., Tsuboi, K. & Gage, F. H. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine. Brain Res. 883, 192-204 (2000).
118. Koike, H. et al. Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease. Gene Ther. 13, 1639-1644 (2006).
119. Yasuhara, T. et al. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res. 1038, 1-10 (2005).
120. Casper, D. et al. Enhanced vascularization and survival of neural transplants with ex vivo angiogenic gene transfer. Cell Transplant. 11, 331-349 (2002).
121. Timmer, M. et al. Enhanced survival, reinnervation, and functional recovery of intrastriatal dopamine grafts co-transplanted with Schwann cells overexpressing high molecular weight FGF-2 isoforms. Exp. Neurol. 187, 118-136 (2004).
122. Lindvall, O. & Kokaia, Z. Stem cells for the treatment of neurological disorders. Nature 441, 1094-1096 (2006).
123. Jin, K. et al. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 102, 18189-18194 (2005).
124. Zucchini, S., Barbieri, M. & Simonato, M. Alterations in seizure susceptibility and in seizure-induced plasticity after pharmacologic and genetic manipulation of the fibroblast growth factor-2 system. Epilepsia 46 (Suppl. 5), 52-58 (2005).
125. Ruffini, F. et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 8, 1207-1213 (2001).
126. Savino, C. et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J. Neuroimmunol. 172, 27-37 (2006).
127. Kleiter, I. et al. Inhibition of Smad7, a negative regulator of TGF-β signaling, suppresses autoimmune encephalomyelitis. J. Neuroimmunol. 187, 61-73 (2007).
128. Veldhoen, M., Hocking, R. J., Flavell, R. A. & Stockinger, B. Signals mediated by transforming growth factor-β initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nature Immunol. 7, 1151-1156 (2006).
129. Greenberg, D. A. & Jin, K. Growth factors and stroke. NeuroRx 3, 458-465 (2006).
130. Tuszynski, M. H. Nerve growth factor gene delivery: animal models to clinical trials. Dev. Neurobiol. 67, 1204-1215 (2007).
131. Weinstein, B. M. Vessels and nerves: marching to the same tune. Cell 120, 299-302 (2005).
132. Carmeliet, P. & Tessier-Lavigne, M. Common mechanisms of nerve and blood vessel wiring. Nature 436, 193-200 (2005).
133. Schwarz, Q. et al. Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev. 18, 2822-2834 (2004).
134. Paris, D. et al. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci. Lett. 366, 80-85 (2004).
135. Greenberg, S. M., Gurol, M. E., Rosand, J. & Smith, E. E. Amyloid angiopathy-related vascular cognitive impairment. Stroke 35, 2616-2619 (2004).
136. Casserly, I. & Topol, E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146 (2004).
137. 2+ signaling and the microvasculature in experimental mice models of Alzheimer's disease. Ann. NY Acad. Sci. 1097, 40-50 (2007).
138. Niwa, K. et al. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283, H315-H323 (2002).
139. Johnson, K. A. & Albert, M. S. Perfusion abnormalities in prodromal AD. Neurobiol. Aging 21, 289-292 (2000).
140. Iadecola, C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nature Rev. Neurosci. 5, 347-360 (2004).
141. Kaletta, T. & Hengartner, M. O. Finding function in novel targets: C. elegans as a model organism. Nature Rev. Drug Discov. 5, 387-398 (2006).
142. Vande Velde, C. & Cleveland, D. W. VEGF: multitasking in ALS. Nature Neurosci. 8, 5-7 (2005).
143. Cleaver, O. & Melton, D. A. Endothelial signaling during development. Nature Med. 9, 661-668 (2003).
144. Chen, K. S. et al. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J. Neurosci. 17, 7288-7296 (1997).
145. Jackson, E. L. et al. PDGFRα-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 51, 187-199 (2006).
146. Garcia de Yebenes, J., Yebenes, J. & Mena, M. A. Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease. Neurotox. Res. 2, 115-137 (2000).
147. Simonato, M., Tongiorgi, E. & Kokaia, M. Angels and demons: neurotrophic factors and epilepsy. Trends Pharmacol. Sci. 27, 631-638 (2006).
148. Royo, N. C. et al. Hippocampal vulnerability following traumatic brain injury: a potential role for neurotrophin-4/5 in pyramidal cell neuroprotection. Eur. J. Neurosci. 23, 1089-1102 (2006).
149. Torres-Peraza, J. et al. Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors. Neuroscience 144, 462-471 (2007).
150. Schratzberger, P. et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. 107, 1083-1092 (2001).
151. Fruttiger, M. et al. Defective oligodendrocyte development and severe hypomyelination in PDGF-A knockout mice. Development 126, 457-467 (1999).
152. Liu, S., Yu, D., Xu, Z. P., Riordan, J. F. & Hu, G. F. Angiogenin activates Erk1/2 in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 287, 305-310 (2001).
153. Xu, Z., Monti, D. M. & Hu, G. Angiogenin activates human umbilical artery smooth muscle cells. Biochem. Biophys. Res. Commun. 285, 909-914 (2001).
154. Subramanian, V., Crabtree, B. & Acharya, K. R. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum. Mol. Genet. 17, 130-149 (2008).
155. Mason, I. Initiation to end point: the multiple roles of fibroblast growth factors in neural development. Nature Rev. Neurosci. 8, 583-596 (2007).
156. Konig, H. G., Kogel, D., Rami, A. & Prehn, J. H. TGF-β1 activates two distinct type I receptors in neurons: implications for neuronal NF-κB signaling. J. Cell Biol. 168, 1077-1086 (2005).
157. Svensson, J. et al. Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice. J. Endocrinol. 189, 617-627 (2006). In this study, IGF1 production was inactivated in the liver of adult mice, resulting in impaired spatial working and reference memory as well as neurochemical disturbances that suggested synaptic dysfunction and early neurodegeneration. The decline in serum IGF1 with increasing age might therefore be important for the age-related decline in memory function.
158. Cheng, J. & Du, J. Mechanical stretch simulates proliferation of venous smooth muscle cells through activation of the insulin-like growth factor-1 receptor. Arterioscler. Thromb. Vasc. Biol. 27, 1744-1751 (2007).
159. Powell, E. M. et al. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J. Neurosci. 23, 622-631 (2003).
160. Sun, W., Funakoshi, H. & Nakamura, T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J. Neurosci. 22, 6537-6548 (2002).
161. Kato, N. et al. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes 54, 846-854 (2005).
162. Morishita, R. et al. Potential role of a novel vascular modulator, hepatocyte growth factor (HGF), in cardiovascular disease: characterization and regulation of local HGF system. J. Atheroscler. Thromb. 4, 12-19 (1997).
163. Ebens, A. et al. Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron 17, 1157-1172 (1996).
164. Amin, D. N., Hida, K., Bielenberg, D. R. & Klagsbrun, M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 66, 2173-2180 (2006).
165. Chen, Z. Y., Asavaritikrai, P., Prchal, J. T. & Noguchi, C. T. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J. Biol. Chem. 282, 25875-25883 (2007). This study illustrated that neural progenitor cells express EPOR at higher levels than mature neurons, that EPO stimulates the proliferation of embryonic neural progenitor cells and that endogenous EPO contributes to neural-progenitor-cell proliferation and maintenance.
166. Nadam, J. et al. Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus. Neurobiol. Dis. 25, 412-426 (2007).
167. Leist, M. et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305, 239-242 (2004).
168. Noguchi, C. T., Asavaritikrai, P., Teng, R. & Jia, Y. Role of erythropoietin in the brain. Crit. Rev. Oncol. Hematol. 64, 159-171 (2007).